Tag archive for ‘multiple sclerosis treatment’
Niva Goldberg On Thursday, June 18th, 2015

U.S. court invalidates Teva’s Copaxone patent

The U.S. Court of Appeals has again ruled that Teva Pharmaceuticals Industries Ltd.’s patent for its top-selling multiple sclerosis treatment Copaxone is invalid. A Teva spokeswoman said that the company is More...

Shiri Habib-Valdhorn On Tuesday, January 27th, 2015

Teva rivals urge US court to expedite Copaxone suit

Copaxone’s patent remains in force at least until the Federal Circuit Appeals Court reconsiders the case. The rivals of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) who are developing a More...

Globes On Monday, January 26th, 2015

Teva gets first “Sell” recommendation

Berenberg analysts see insurance companies pressuring MS patients to switch to generic versions of Copaxone. Last year, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) posted its highest return More...

Nadav Neuman On Wednesday, January 21st, 2015

US Supreme Court upholds Copaxone patent

The ruling means Teva’s flagship multiple sclerosis treatment’s patent remains valid until September 2015.   The US Supreme Court has ruled in favor of Teva Pharmaceutical Industries Ltd. (NYSE: More...

Gil Tanenbaum On Thursday, November 13th, 2014

Teva’s MS Drug Copaxone Looking for Approval in Japan

Teva’s Copaxone, a new medication under development for the treatment of multiple sclerosis treatment Copaxone, has gotten closer to getting approval for marketing in Japan from that nation’s regulatory More...

Jewish Business News Correspondent On Thursday, September 11th, 2014

Teva finds double-dose Copaxone halves side-effects

– A 50% reduction in adverse side-effects was reported with the three-times-a-week 40 mg MS injection. – – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has published results More...

Globes On Thursday, July 31st, 2014

Teva reports falling Copaxone sales, sharp rise in 40mg use

– Sales of the multiple sclerosis treatment were down 12% in the second quarter. – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) reported higher profit and revenue in its financial More...

Jewish Business News Service On Wednesday, December 4th, 2013

Teva and Takeda Announce Agreement for Glatiramer Acetate (Copaxone) for Multiple Sclerosis Treatment in Japan

–   Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Takeda Pharmaceutical Company Limited ((TSE: 4502) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda More...

פטיש LAW court Illustration
Globes On Wednesday, July 17th, 2013

US court : Teva loses Copaxone patent suit

– The Southern District of New York dismissed Teva’s lawsuit against Mylan for the infringement of patents on its MS treatment. – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) More...

Wordpress site Developed by Fixing WordPress Problems